Adriamycin mouse model: a variable but reproducible model of tracheo-oesophageal malformations.
A spectrum of tracheo-oesophageal malformations is seen in humans: oesophageal atresia, tracheal agenesis and laryngotracheo-oesophageal clefts. They are thought to share a common but unknown aetiology. These birth defects are frequently associated with other VACTERL anomalies. The adriamycin rat model (ARM) has proved to be a valuable model of the VACTERL anomalies, illustrating the dysmorphogenesis of oesophageal atresia and tracheal agenesis. As organogenesis relies on temporaspatially co-ordinated signalling systems, the next step would be to study the molecular pathogenesis of tracheo-oesophageal malformations. However, the mouse is the foremost mammal studied by developmental biologists, offering an expanding wealth of knowledge and scientific research techniques with which to investigate these anomalies. A limited dose response analysis of the teratogenicity of adriamycin in the mouse has identified a dose and timing of injections that produced tracheo-oesophageal malformations and other VACTERL anomalies. A clear account of the types and variability of the tracheo-oesophageal malformations produced by this dose is essential in order to be able to plan and interpret any future investigations of early gestation fetuses. CBA/Ca mice were accurately time-mated (n = 10). Nine dams received intraperitoneal injections of adriamycin (6 mg/kg) and one control dam received saline injections, on days 7 and 8. Fetuses were harvested on day 18, near term. Tracheo-oesophageal malformations were examined by dissecting microscope and serial transverse sections. Results are reported in the standard teratological manner as mean percentage per litter (+/-SEM). The resorption rate of the adriamycin treated fetuses was 50.4%. There were 29 adriamycin treated fetuses for inspection. Tracheo-oesophageal malformations were found in 29.2% (+/-10.3), affecting five out of nine litters. Oesophageal atresia occurred in 15.6% (+/-8.1), laryngotracheo-oesophageal cleft in 10.4% (+/-7) and tracheal agenesis in 3.1% (+/-3.1). All of these malformations occurred with a tracheo-oesophageal fistula. Unlike the ARM, the AMM can produce fetuses with complete laryngotracheo-oesophageal cleft as well as oesophageal atresia or tracheal agenesis. Their occurrence was found to be reproducible but variable. These are important considerations when planning and interpreting experiments using this model.
Dawrant
Michael J
MJ
National Children's Hospital, Tallaght, Dublin 24, Ireland.
Giles
Shay
S
Bannigan
John
J
Puri
Prem
P
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000633:toxicity*; D004933:Esophageal Atresia / Q000139:chemically induced / Q000196:embryology; D004935:Esophageal Diseases / Q000139:chemically induced* / Q000196:embryology; D004947:Esophagus / Q000002:abnormalities* / Q000187:drug effects / Q000196:embryology; D005260:Female; D051379:Mice; D008808:Mice, Inbred CBA; D015203:Reproducibility of Results; D012965:Sodium Chloride / Q000008:administration & dosage; D014132:Trachea / Q000002:abnormalities* / Q000187:drug effects / Q000196:embryology; D014133:Tracheal Diseases / Q000139:chemically induced* / Q000196:embryology; D014138:Tracheoesophageal Fistula / Q000139:chemically induced / Q000196:embryology
D000903:Antibiotics, Antineoplastic; D012965:Sodium Chloride; D004317:Doxorubicin